PT  - JOURNAL ARTICLE
AU  - Adams, Mark J
AU  - Thorp, Jackson G
AU  - Jermy, Bradley S
AU  - Kwong, Alex S F
AU  - Kõiv, Kadri
AU  - Grotzinger, Andrew D
AU  - Nivard, Michel G
AU  - Marshall, Sally
AU  - Milaneschi, Yuri
AU  - Baune, Bernhard T
AU  - Müller-Myhsok, Bertram
AU  - Penninx, Brenda WJH
AU  - Boomsma, Dorret I
AU  - Levinson, Douglas F
AU  - Breen, Gerome
AU  - Pistis, Giorgio
AU  - Grabe, Hans J
AU  - Tiemeier, Henning
AU  - Berger, Klaus
AU  - Rietschel, Marcella
AU  - Magnusson, Patrik K
AU  - Uher, Rudolf
AU  - Hamilton, Steven P
AU  - Lucae, Susanne
AU  - Lehto, Kelli
AU  - Li, Qingqin S
AU  - Byrne, Enda M
AU  - Hickie, Ian B
AU  - Martin, Nicholas G
AU  - Medland, Sarah E
AU  - Wray, Naomi R
AU  - Tucker-Drob, Elliot M
AU - Estonian Biobank Research Team
AU - Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
AU  - Lewis, Cathryn M
AU  - McIntosh, Andrew M
AU  - Derks, Eske M
TI  - Genetic structure of major depression symptoms across clinical and community cohorts
AID  - 10.1101/2023.07.05.23292214
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.05.23292214
4099  - http://medrxiv.org/content/early/2023/07/07/2023.07.05.23292214.short
4100  - http://medrxiv.org/content/early/2023/07/07/2023.07.05.23292214.full
AB  - Diagnostic criteria for major depressive disorder allow for heterogeneous symptom profiles but genetic analysis of major depressive symptoms has the potential to identify clinical and aetiological subtypes. There are several challenges to integrating symptom data from genetically-informative cohorts, such as sample size differences between clinical and community cohorts and various patterns of missing data. We conducted genome-wide association studies of major depressive symptoms in three clinical cohorts that were enriched for affected participants (Psychiatric Genomics Consortium, Australian Genetics of Depression Study, Generation Scotland) and three community cohorts (Avon Longitudinal Study of Parents and Children, Estonian Biobank, and UK Biobank). We fit a series of confirmatory factor models with factors that accounted for how symptom data was sampled and then compared alternative models with different symptom factors. The best fitting model had a distinct factor for Appetite/Weight symptoms and an additional measurement factor that accounted for missing data patterns in the community cohorts (use of Depression and Anhedonia as gating symptoms). The results show the importance of assessing the directionality of symptoms (such as hypersomnia versus insomnia) and of accounting for study and measurement design when meta-analysing genetic association data.Competing Interest StatementCL sits on the SAB for Myriad Neuroscience, has received consultancy fees from UCB, and speaker fees from SYNLAB. HJG has received travel grants and speaker's honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care.Funding StatementAGDS supported by National Health and Medical Research Council (NHMRC) (1086683, 1145645, 1078901, 1087889, 1173790); ALSPAC supported by the Medical Research Council and Wellcome Trust (217065/Z/19/Z). Estonian Biobank supported by the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012). NTR-NESDA supported by Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL; 184.021.007 and 184.033.111), National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Funding for NTR is acknowledged from NWO-MW 904-61-193; NWO 985-10-002; NWO 904-61-090; Royal Netherlands Academy of Science Professor Award (PAH/6635) to DIB; European Research Council (ERC-230374). Funding for the infrastructure of the NESDA study (www.nesda.n) was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002); the Center for Medical Systems Biology (CSMB, NWO Genomics), VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum. MJA, ASFK, and AMMc are supported by the Wellcome Trust (104036/Z/14/Z, 220857/Z/20/Z). SEM is supported by NHMRC APP1172917, APP1138514 and MRF1200644. ADG, and MGN and EMTD were supported by National Institute of Mental Health grant R01MH120219. KL and KK were supported by the Estonian Research Council grant PSG615. UKB analysis conducted under project 4844. This work made use of the NL Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara and resources provided by the Edinburgh Compute and Data Facility (ECDF) (http://www.ecdf.ed.ac.uk/). The Psychiatric Genomics Consortium (PGC) has received major funding from the National Institute of Mental Health and the National Institute on Drug Abuse (U01 MH109528, U01 MH109532, U01 MH094421, U01 MH085520). This paper represents independent research part-funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ALSPAC Ethics and Law Committee of the University of Bristol gave ethical approval for this work. Human Research Ethics Committee of QIMR Berghofer Medical Research Institute gave ethical approval for this work. Estonian Committee on Bioethics and Human Research of the Estonian Ministry of Social Affairs gave ethical approval for this work. Tayside Committee on Medical Research Ethics gave ethical approval for this work. The Research Ethics Committee of the UK Biobank gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMeta-analysed summary statistics are available for download from the PGC website. Individual-level PGC data is available by application to the PGC Data Access Committee. Data from Estonian Biobank, UK Biobank, and ALSPAC are available to bonafide researchers upon application. Data from AGDS is available for collaboration by contacting NGM (Nick.Martin@qimrberghofer.edu.au). https://www.med.unc.edu/pgc/download-results https://www.med.unc.edu/pgc/shared-methods/ https://genomics.ut.ee/en/content/estonian-biobank https://www.ukbiobank.ac.uk http://www.bristol.ac.uk/alspac/